API2-MALT1 Fusion Gene in Colorectal Lymphoma

Sumie Takase Sakugawa; Tadashi Yoshino; Shigeo Nakamura; Hiroshi Inagaki; Yoshito Sadahira; Hirokazu Nakamine; Mitsukuni Okabe; Koichi Ichimura; Mitsune Tanimoto; Tadaatsu Akagi

doi:10.1097/01.MP.0000097283.47637.58

API2-MALT1 Fusion Gene in Colorectal Lymphoma

Sumie Takase Sakugawa, Tadashi Yoshino, Shigeo Nakamura, Hiroshi Inagaki, Yoshito Sadahira, Hirokazu Nakamine, Mitsukuni Okabe, Koichi Ichimura, Mitsune Tanimoto, Tadaatsu Akagi

Research output: Contribution to journal › Article › peer-review

30 Citations (Scopus)

Abstract

The API2-MALT1 fusion gene was originally identified from a t(11;18)(q21;q21) translocation, a specific chromosomal abnormality that is found in mucosa-associated lymphoid tissue (MALT) lymphoma. Gastric MALT lymphomas positive for the API2-MALT1 fusion gene do not respond to Helicobacter pylori-eradication therapy, but otherwise, the incidence and clinicopathological behavior of colorectal MALT lymphoma with this genetic abnormality are unclear. We examined the API2-MALT1 fusion by multiplex RT-PCR method in 47 cases of MALT lymphoma and 13 cases of diffuse large B-cell lymphoma and evaluated the relevance of API2-MALT1 positivity to the clinical and pathological features. The mean ages of MALT lymphoma and diffuse large B-cell lymphoma patients were 65 (range, 37-87 y) and 58 (range, 14-85 y) years, respectively. API2-MALT1 fusion genes were detected in seven cases (15%) of MALT lymphoma and one case (8%) of diffuse large B-cell lymphoma. In MALT lymphomas, the tumor size in API2-MALT1-positive cases was 62 ± 39 mm (mean ± SD), statistically larger than that in API2-MALT1-negative cases (25 ± 19 mm; P < .01). The API2-MALT1-positive cases demonstrated more advanced clinical stages and a male predominance, compared with API2-MALT1-negative cases. Thus, API2-MALT1-positive tumors should be cared for as a more aggressive subgroup and be followed for a longer time.

Original language	English
Pages (from-to)	1232-1241
Number of pages	10
Journal	Modern Pathology
Volume	16
Issue number	12
DOIs	https://doi.org/10.1097/01.MP.0000097283.47637.58
Publication status	Published - Dec 2003

Keywords

API2
Large intestine
MALT lymphoma
MALT1
RT-PCR

ASJC Scopus subject areas

Pathology and Forensic Medicine

Access to Document

10.1097/01.MP.0000097283.47637.58

Cite this

@article{28695ab3e7a84cb6ac23691b059736f8,

title = "API2-MALT1 Fusion Gene in Colorectal Lymphoma",

abstract = "The API2-MALT1 fusion gene was originally identified from a t(11;18)(q21;q21) translocation, a specific chromosomal abnormality that is found in mucosa-associated lymphoid tissue (MALT) lymphoma. Gastric MALT lymphomas positive for the API2-MALT1 fusion gene do not respond to Helicobacter pylori-eradication therapy, but otherwise, the incidence and clinicopathological behavior of colorectal MALT lymphoma with this genetic abnormality are unclear. We examined the API2-MALT1 fusion by multiplex RT-PCR method in 47 cases of MALT lymphoma and 13 cases of diffuse large B-cell lymphoma and evaluated the relevance of API2-MALT1 positivity to the clinical and pathological features. The mean ages of MALT lymphoma and diffuse large B-cell lymphoma patients were 65 (range, 37-87 y) and 58 (range, 14-85 y) years, respectively. API2-MALT1 fusion genes were detected in seven cases (15%) of MALT lymphoma and one case (8%) of diffuse large B-cell lymphoma. In MALT lymphomas, the tumor size in API2-MALT1-positive cases was 62 ± 39 mm (mean ± SD), statistically larger than that in API2-MALT1-negative cases (25 ± 19 mm; P < .01). The API2-MALT1-positive cases demonstrated more advanced clinical stages and a male predominance, compared with API2-MALT1-negative cases. Thus, API2-MALT1-positive tumors should be cared for as a more aggressive subgroup and be followed for a longer time.",

keywords = "API2, Large intestine, MALT lymphoma, MALT1, RT-PCR",

author = "Sakugawa, {Sumie Takase} and Tadashi Yoshino and Shigeo Nakamura and Hiroshi Inagaki and Yoshito Sadahira and Hirokazu Nakamine and Mitsukuni Okabe and Koichi Ichimura and Mitsune Tanimoto and Tadaatsu Akagi",

note = "Funding Information: Copyright {\textcopyright} 2003 by The United States and Canadian Academy of Pathology, Inc. VOL. 16, NO. 12, P. 1232, 2003 Printed in the U.S.A. Date of acceptance: August 15, 2003. Supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan. Address reprint requests to: Tadashi Yoshino, M.D., Ph.D., Department of Pathology, Okayama University Graduate School of Medicine and Dentistry, 2-5-1 Shikata-cho, Okayama 700-8558, Japan; fax: 81 (86) 235-7156; e-mail: yoshino@md.okayama-u.ac.jp.",

year = "2003",

month = dec,

doi = "10.1097/01.MP.0000097283.47637.58",

language = "English",

volume = "16",

pages = "1232--1241",

journal = "Modern Pathology",

issn = "0893-3952",

publisher = "Nature Publishing Group",

number = "12",

}

TY - JOUR

T1 - API2-MALT1 Fusion Gene in Colorectal Lymphoma

AU - Sakugawa, Sumie Takase

AU - Yoshino, Tadashi

AU - Nakamura, Shigeo

AU - Inagaki, Hiroshi

AU - Sadahira, Yoshito

AU - Nakamine, Hirokazu

AU - Okabe, Mitsukuni

AU - Ichimura, Koichi

AU - Tanimoto, Mitsune

AU - Akagi, Tadaatsu

N1 - Funding Information: Copyright © 2003 by The United States and Canadian Academy of Pathology, Inc. VOL. 16, NO. 12, P. 1232, 2003 Printed in the U.S.A. Date of acceptance: August 15, 2003. Supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan. Address reprint requests to: Tadashi Yoshino, M.D., Ph.D., Department of Pathology, Okayama University Graduate School of Medicine and Dentistry, 2-5-1 Shikata-cho, Okayama 700-8558, Japan; fax: 81 (86) 235-7156; e-mail: yoshino@md.okayama-u.ac.jp.

PY - 2003/12

Y1 - 2003/12

N2 - The API2-MALT1 fusion gene was originally identified from a t(11;18)(q21;q21) translocation, a specific chromosomal abnormality that is found in mucosa-associated lymphoid tissue (MALT) lymphoma. Gastric MALT lymphomas positive for the API2-MALT1 fusion gene do not respond to Helicobacter pylori-eradication therapy, but otherwise, the incidence and clinicopathological behavior of colorectal MALT lymphoma with this genetic abnormality are unclear. We examined the API2-MALT1 fusion by multiplex RT-PCR method in 47 cases of MALT lymphoma and 13 cases of diffuse large B-cell lymphoma and evaluated the relevance of API2-MALT1 positivity to the clinical and pathological features. The mean ages of MALT lymphoma and diffuse large B-cell lymphoma patients were 65 (range, 37-87 y) and 58 (range, 14-85 y) years, respectively. API2-MALT1 fusion genes were detected in seven cases (15%) of MALT lymphoma and one case (8%) of diffuse large B-cell lymphoma. In MALT lymphomas, the tumor size in API2-MALT1-positive cases was 62 ± 39 mm (mean ± SD), statistically larger than that in API2-MALT1-negative cases (25 ± 19 mm; P < .01). The API2-MALT1-positive cases demonstrated more advanced clinical stages and a male predominance, compared with API2-MALT1-negative cases. Thus, API2-MALT1-positive tumors should be cared for as a more aggressive subgroup and be followed for a longer time.

AB - The API2-MALT1 fusion gene was originally identified from a t(11;18)(q21;q21) translocation, a specific chromosomal abnormality that is found in mucosa-associated lymphoid tissue (MALT) lymphoma. Gastric MALT lymphomas positive for the API2-MALT1 fusion gene do not respond to Helicobacter pylori-eradication therapy, but otherwise, the incidence and clinicopathological behavior of colorectal MALT lymphoma with this genetic abnormality are unclear. We examined the API2-MALT1 fusion by multiplex RT-PCR method in 47 cases of MALT lymphoma and 13 cases of diffuse large B-cell lymphoma and evaluated the relevance of API2-MALT1 positivity to the clinical and pathological features. The mean ages of MALT lymphoma and diffuse large B-cell lymphoma patients were 65 (range, 37-87 y) and 58 (range, 14-85 y) years, respectively. API2-MALT1 fusion genes were detected in seven cases (15%) of MALT lymphoma and one case (8%) of diffuse large B-cell lymphoma. In MALT lymphomas, the tumor size in API2-MALT1-positive cases was 62 ± 39 mm (mean ± SD), statistically larger than that in API2-MALT1-negative cases (25 ± 19 mm; P < .01). The API2-MALT1-positive cases demonstrated more advanced clinical stages and a male predominance, compared with API2-MALT1-negative cases. Thus, API2-MALT1-positive tumors should be cared for as a more aggressive subgroup and be followed for a longer time.

KW - API2

KW - Large intestine

KW - MALT lymphoma

KW - MALT1

KW - RT-PCR

UR - http://www.scopus.com/inward/record.url?scp=0347623268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347623268&partnerID=8YFLogxK

U2 - 10.1097/01.MP.0000097283.47637.58

DO - 10.1097/01.MP.0000097283.47637.58

M3 - Article

C2 - 14681324

AN - SCOPUS:0347623268

SN - 0893-3952

VL - 16

SP - 1232

EP - 1241

JO - Modern Pathology

JF - Modern Pathology

IS - 12

ER -

API2-MALT1 Fusion Gene in Colorectal Lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this